Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model
Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS
ASH is the world’s premier conference focussing on haematological malignancies
6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that it will present a poster detailing POLB 001’s efficacy in reducing immunotherapy-induced CRS in an in vivo animal model, at the 66th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, taking place 7-10 December 2024 in San Diego, California.
